Main > ONCOLOGY (**) > Lymphoma>NHL>B-Cell>DLBCL R/R*** > Treatment > CH. A. CD19. ADC>2 Lines of

---

Systemic Therapy

CH. A. CD19. ADC>2 Lines of's subsections
(*) EU CE Mark Date: 2022. 12.21.
(*) USA Approval Date: 2021. 04.23.
Company
Generic Name: Loncastuximab Tesirin
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 2
Patent>UpDate: 2021. 04.27.
TradeMark
TradeMark Web-Site

CH. A. CD19. ADC>2 Lines of's products
This section has no products